CEL-SCI Corporation (NYSE:CVM) announced that the latest results from its pivotal Phase 3 study of Multikine, a presurgical cancer immunotherapy, were presented at the European Society for Radiotherapy and Oncology (ESTRO) 2023 Congress.
CEL-SCI’s IT-MATTERS Phase 3 study reported a statistically significant 14.1% absolute 5-year overall survival benefit in the intent-to-treat (ITT) subjects who were categorized as a lower risk to recurrence (LR) and received Multikine followed by surgery and radiotherapy, as compared to control LR subjects who received only standard of care (SOC) (surgery plus radiotherapy).
Related: CEL-SCI’s Lead Head & Neck Cancer Candidate Shows 43% Survival Extension.
The histopathology analysis showed an association with improved overall survival, progression-free survival, and local, regional control that significantly favored Multikine-treated [(61/279 or 21.9% >> 2.5% by chance alone) vs. SOC-treated (5/279 (or 1.9% < 2.5% by chance alone)].
Overall survival of 63.9% vs. 44.4%, with Progression Free Survival of 56.9%.
HP LR Multikine-treated subjects had a significantly lower (39.1% [45/115]) death rate versus a 53.7% (51/95) death rate for HP LR SOC alone.
Price Action: CVM shares are up 9.17% at $2.62 on the last check Monday.
